EMA restructures organization.
The European Medicines Agency is moving forward with plans to restructure the organization. EMA’s management team began transitioning to a new structure on August 1, 2013.
The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.
EMA will announce details of the new structure of the organization in September 2013.
Source:
European Medicines Agency
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.